Etiology, Symptoms, Neuropathology and Management of Alzheimer’s Disease: A Neurodegenerative Disorder
Abstract
Alzheimer’s disease (AD) is a neurological disorder reflected by memory loss and affecting daily living activities. The pathological alterations of Alzheimer’s disease are mainly through neuritic plaques which are the accumulation of beta-amyloid protein and also neurofibrillary tangles. This review has been accomplished on various pathological alterations, causes, treatment and management of Alzheimer’s disease targeting towards cholinergic deficiency, inflammation and oxidative stress. The management and therapy of Alzheimer’s disease include Memantine, cholinesterase inhibitors, ACE inhibitors, secretase inhibitors and anti-
inflammatory drugs including various vitamins, minerals and herbal drugs. This review aims to focus on the mechanism of oxidative stress including its role in the progression of the disease.
How to cite this article: Vishwakarma VK, Paswan SK, Shukla N et al. Etiology, Symptoms, Neuropathology and Management of Alzheimer’s Disease: A Neurodegenerative Disorder. Int J Adv Res Pharm Edu 2020; 2(1): 16-23.
References
Y. Huang, L. Mucke, Cell 2012, 148, 1204–1222.
Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55:1158-66.
Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammtion 2006;3:5.
Marklund SL, Westman NG, Lundgren E, Roos G. Copper- and Zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res 1982;42:1955-61.
Guest AJ, Grant RS. Effect of dietary derived antioxidants on the central nervous system. Int J Nutr Pharmacol Neurol Dis 2012;2:185-97.
Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002;33:182-91.
Nivsarkar M, Banerjee A, Padh H. Cyclooxygenase inhibitors: A novel direction for Alzheimer's management. Pharmacol Rep 2008;60:692-8.
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secre- tase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8.
Singhal AK, Naithani V, Bangar OP. Medicinal plants with a potential to treat alzheimer and associated symptoms. Int J Nutr Pharmacol Neurol Dis 2012;2:84-91.
Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 2006;209:598-603.
Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurode- generative disorders. Behav Brain Funct 2006;2:15.
Turnitin:
Megan Steele, Grant Stuchbury, Gerald Münch. “The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition”Experimental Gerontology, Volume 42, Issues 1–2, January–February 2007, Pages 28–36.
reference and 3. Wollen, Keith A. “Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Alternative Medicine Review, volume: 15, Issue-3,Sept 2010, 223-44.
Giorgio Silvestrelli, Alessia Lanarim Lucilla Parnettia,Daniele Tomassonib,Francesco Amenta. ‘Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology, Mechanisms of Ageing and Development, Volume 127, Issue 2, February 2006, Pages 148–157
David G. Munoz, Howerd Feldman, “ Causes of Alzheimer’disease” CMAJ Medical knowledge that matters, 2000, volume-162, issue-1, 65-72.
http://www.helpguide.org/articles/alzheimers-dementia/alzheimers-disease.htm acessed on 04/09/2015
Prerna Upadhyaya, Vikas Seth, Mushtaq Ahmed. “Therapy of Alzheimer’s disease- An Update’ African Journal of Pharmacy and Pharmacology, 2010, Vol-4 (6), 408-421.
William Thies and Laura Bleiler. “2013 Alzheimer's disease facts and figures”, Alzheimer’s and dementia, 2013, Volume 9, Issue 2, Pages 208–245
Amos D. Korczyn, Veronika Vakhapova. The prevention of the dementia epidemic, Journal of the Neurological sciences, June 15, 2007Volume 257, Issues 1-2, Pages 2–4
D. Allan Butterfield, Marzia Perluigi, Tanea Reed, Tasneem Muharib, Christopher P. Hughes, Renã A.S. Robinson, and Rukhsana Sultana. Antioxidants & Redox Signaling. December 1, 2012, 17(11): 1610-1655.
Jose Jose Miguel Rubio-Perez, Juana Maria Morillas-Ruiz, Oxidative damage in Alzheimer’s disease, Therapeutics targets for neurological diseases, Vol 1, No 1 (2014), 1-49.
Michael Heinrich, Hooi Lee Teoh. Galanthamine from snowdrop—the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge, Journal of Ethnopharmacology, Volume 92, Issues 2–3, June 2004, Pages 147–162
Anil Kumar, Arti Singh, Ekavali, ‘A review on Alzheimer's disease pathophysiology and its management: an update’ Pharmacological Reports, Volume 67, Issue 2,2015, Pages 195–203
